Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lubiprostone helps relieve constipation in short-term 4-week studies. There are limited data on long-term pharmacological treatment with lubiprostone for chronic idiopathic constipation. AIMS: To examine the long-term safety and effectiveness of lubiprostone in patients with chronic idiopathic constipation. METHODS: In this prospective, multicenter, open-labeled trial, 248 patients aged ≥18 years with chronic idiopathic constipation were directed to take lubiprostone 24 mcg BID as needed for 48 weeks. Patients were allowed to decrease the dose in response to the perceived severity of constipation and need for relief. Hematology and chemistry profiles and assessment of constipation symptoms and its severity were performed at all visits. Adverse events (AEs) were recorded. RESULTS: Of the 248 patients who entered the trial, 127 (51%) completed the trial. A dose reduction was observed in 17% of the patients, resulting in an average study medication exposure across the study of approximately 1.7 capsules (or approximately 40.8 mcg) per day. The most common treatment-related AEs were nausea (19.8%), diarrhea (9.7%), abdominal distension (6.9%), headache (6.9%), and abdominal pain (5.2%). No deaths were reported and of the 16 reported serious AEs, one was considered possibly treatment related. Average changes in serum electrolytes were not clinically relevant at any time point during the study. On average, lubiprostone significantly (p < 0.0001) reduced patient-reported constipation severity, abdominal bloating, and abdominal discomfort across 48 weeks when compared to baseline. CONCLUSIONS: During this 48-week open-label study, lubiprostone was well tolerated. Bowel symptoms consistently improved over 48 weeks in adult patients with chronic idiopathic constipation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of colonic symptoms and the irritable bowel syndrome
Talley, N. J., Zinsmeister, A. R., van Dyke, C., & Melton, L. J. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90717-y · Cited by 648 · cited 1×
“However, these data likely underestimate the problem, since only a minority of people with constipation seek medical care [5, 6].”
Camilleri, M., Bharucha, A. E., Ueno, R., Burton, D., Thomforde, G. M., Baxter, K., McKinzie, S., & Zinsmeister, A. R. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00264.2005 · Cited by 253
Self-citationCorazziari, E., Badiali, D., Bazzocchi, G., Bassotti, G., Roselli, P., Mastropaolo, G., Lucà, M. G., Galeazzi, R., & Peruzzi, E. (2000) · Gut · doi:10.1136/gut.46.4.522 · Cited by 202 · cited 1×
“Placebo-controlled studies of long duration are difficult to perform due to the high dropout rate of patients in the placebo arm [ 22 ].”
Efficacy and safety of lubiprostone in patients with chronic constipation
Barish, C. F., Drossman, D., Johanson, J. F., & Ueno, R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1068-x · Cited by 192 · cited 7×
“, 4 weeks) double-blinded, placebo-controlled studies [16, 17].”
InfluentialSelf-citation
Cited by
Gastrointestinal Dysfunction in Parkinson’s Disease
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00007-1 · Cited by 1,016
Diagnosis and management of chronic constipation in adults
Rao, S. S. C., Rattanakovit, K., & Patcharatrakul, T. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.53 · Cited by 337
Self-citationSharma, A., Rao, S. S. C., Kearns, K., Orleck, K. D., & Waldman, S. A. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16369 · Cited by 84
Self-citationAnalysis of nausea in clinical studies of lubiprostone for the treatment of constipation disorders
Cryer, B., Drossman, D. A., Chey, W. D., Webster, L., Habibi, S., & Wang, M. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4680-1 · Cited by 43
Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments
Müller-Lissner, S. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.773972 · Cited by 31
Metadata
- Authors
- Lembo, A. J., Johanson, J. F., Parkman, H. P., Rao, S. S., Miner, P. B., & Ueno, R.
- Venue
- Digestive Diseases and Sciences
- Published
- 2011-07-19
- Volume
- 56
- Issue
- 9
- Pages
- 2639-45
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2001830981
- Cited by
- 108
- References
- 4
- FWCI
- 8.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation. https://app.cochat.ai/papers/10.1007/s10620-011-1801-0
- The paper
- Lembo, A. J., Johanson, J. F., Parkman, H. P., Rao, S. S., Miner, P. B., & Ueno, R. (2011). Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-011-1801-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.